Congress Program

Monday, 30 October


 07:30 Registration 
 08:30 Session I: Opening
 
08:30-08:35
Welcome to London and a New Approach to Disease Prevention

Julia Manning, Founding Director, 2020health, UK (Co-Chair)

08:35-08:50
Metabesity - 21st Century Solutions to a 21st Century Crisis
Professor Richard Barker, OBE, Founding Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI), UK

08:50-09:10
Metabesity—What, Why and How

Alexander Fleming, Executive Chairman and Founder, Kinexum, USA (Co-Chair)

09:10-09:50
It’s as much about Economics as Science
Joseph C. Cook, Jr.
, Executive Chairman and President, NuSirt BioPharma, USA

09:50-10:00
Overview of the Congress
Lawrence SteinmanGeorge A. Zimmermann Professor and Professor of Pediatrics, Stanford University, USA 
(Co-Chair)                             

 10:00 Session II: Metabesity Targets
 
Moderator: Alexander Fleming

10:00-10:25
Why Can’t I Prevent Obesity and Type 2 Diabetes?
Philip Home, Professor of Diabetes Medicine, Newcastle University, UK

10:25
Coffee Break, Networking and Poster Viewing

 10:55 Session II: Metabesity Targets (continued)
 
10:55-11:20

Common Inflammatory Pathways Associated with Degenerative Disease
Sir John Bell, Regius Professor of Medicine, Oxford University, UK

11:20-11:55
Exploiting Tumour Suppressive Mechanisms for Early Intervention in Cancer
Ashok Venkitaraman, Ursula Zoellner Professor of Cancer Research, University of Cambridge, and Director of the Medical Research Council (MRC) Cancer Unit, UK

11:55-12:20             
NAD Metabolism and Aging
Eric VerdinBuck Institute for Research on Aging, California, USA

12:20-12:30
Panel Discussion

              
 12:30
Lunch Break, Networking and Poster Viewing

 13:30 Session III: Approaches to Metabesity
   
Moderator: Lawrence Steinman

13:30-13:50
Neuroinflammation - Using Big Data to Inform Clinical Practice
Lars FuggerWeatherall Institute of Molecular Medicine, Oxford, UK

13:50-14:10
Interactions between Genetic, Lifestyle/Environmental Risk Factors for Multiple Sclerosis
Tomas Olsson, 
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden  

14:10-14:30
Glucose Metabolism and Dementia
Teresa NiccoliUniversity College London, UK

14:30-14:50
Metabesity and Dementia
Paul M. Matthews
, OBE, MD, DPil, FRCP, FMedSci, Imperial College London, UK

14:50-15:10
Loneliness - A Major Risk Factor for and Target against Metabesity

Lucy Rose, MBA, Physician Assistant
President, Lucy Rose and Associates, LLC and Founder and President, The Cost of Loneliness Project


 15:10
Coffee Break, Networking and Poster Viewing

 15:40 Session III: Approaches to Metabesity (continued)
 
15:40-16:00
What Have We Learned from the Diabetes Prevention Trials?

Itamar Raz, Head, Israeli National Council of Diabetes, Israel

16:00-16:20
Vitamin D and Obesity
Jenny Gunton, Chair of Medicine, University of Sydney, Westmead Hospital, Australia

16:20-16:30
Panel Discussion

 16:30  Session IV: Regulatory Considerations 
 
16:30-17:00
Panel:  What to Expect from Regulatory Agencies, and What Could They Do?
Alexander Fleming (former FDA official)
Lucy Rose (former FDA official)
Brian Harvey (former FDA official)
Philip Home (former advisor to MHRA, EMA, NICE, FDA)

17:00-17:30
Moderated Discussion:  So What?  A Look Ahead to Day 2
Ed Saltzman, Founder and Executive Chairman, Defined Health, USA 

  17:30  
End of Day One


Tuesday, 31 October

 07:00 Registration 
 08:00 Session V: Metabesity Interventions in Development 
 
Moderator:  Brian Harvey

08:00-08:25
Qualifying Clinical Candidates for Anti-Aging Interventions
Nir BarzilaiAlbert Einstein College of Medicine, NY, USA

08:25-08:50
Targeting Aging with Metformin - Proof of Concept
Steve Kritchevsky, Wake Forest Baptist Medical Center, Winston-Salem, USA


08:50-09:15
Hepatic Steatosis, What do NASH Trials Teach Us?
Brian HarveyExecutive Vice President, Scientific and Regulatory Affairs at the non-profit Global Liver Institute, USA

09:15-09:45
Before Pills:  Prevention through Digital Health 
Stephanie Tilenius, Co-Founder and CEO, Vida Health, USA 

 09:45  Session VI: Who Pays? And How?
   09:45-10:30
Conversation:  Implications of Metabesity for Healthcare Systems

Gillian Leng, Deputy Chief Executive, National Institute for Health and Care Excellence (NICE), UK and
Barry Straube, former Chief Medical Officer for the Center for Medicare and Medicaid Services (CMS), USA

 10:30
Coffee Break, Networking and Poster Viewing

 11:00  Session VII: The Most Important Stakeholder:  People
   
11:00-11:20
Ethics for an Age of "Metabesity"?
Joshua HordernAssociate Professor of Christian Ethics, University of Oxford, UK

11:20-11:40
Voice of Patients and Their Advocates
Payal MaratheSenior Associate, Close Concerns, USA

11:40-12:00
Voice of the Would-Be Non-Patient
Julia Manning, Founding Director, 2020health, UK (Co-Chair)

12:00-12:15
Panel Discussion

 12:15 Session VIII: Are New Business Models Needed?
 
12:15-12:40
What Can and Can't Big Pharma Do?
Ed Saltzman, Founder and Executive Chairman of Defined Health, USA

 12:40

Lunch Break, Networking and Poster Viewing

 13:40  Session VIII: Are New Business Models Needed? (Continued)

 
13:40-14:05
Big or Small Pharma, We Need New Business Models
Joseph C. Cook, Jr.Executive Chairman and President, NuSirt BioPharma, USA

14:05-14:25
An Investor's Perspective:  Juvenescence
Anthony Chow
, Chief Executive Officer & Director, MannBioInvest, UK

14:25-14:50
Metabesity.AI
Alex Zhavoronkov, PhD, CEO, Insilico Medicine, USA

14:50-15:15
PRECISION MEDICINE Beyond Cancer: Value Generation Amid Outcome-Based Compensation
Thomas WilckensCEO, InnVentis, Israel

15:15-15:30
Panel Discussion


 15:30 Session IX: Where Do We Go From Here?
 
15:30-16:00
Multilogue:  Take Homes and Next Steps
Julia Manning
(Moderator)
Thomas Seoh, CEO, Kinexum, USA (Moderator)
Speakers and Delegates
  16:00
 End of Congress